Legend Biotech Corp ADR LEGN
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Legend Biotech Announces U.S. FDA Clearance of IND Application for LB2501, an Investigational CD19/CD20 In Vivo CAR-T Therapy
-
Legend Biotech Launches Inaugural ELITE Grant Program to Advance the Next Generation of CAR-T Innovation in Multiple Myeloma
-
Legend Biotech Presents CARVYKTI Data Showing Half of Patients with RRMM Remained Progression-Free and Alive Five Years After a Single Infusion
-
Legend Biotech Appoints Ingrid Zhang as Chief Executive Officer
-
Legend Biotech to Present Updated Long-Term and Real-World Evidence from CARVYKTI Clinical Program at the International Myeloma Society Annual Meeting
-
Legend Biotech to Participate in the Morgan Stanley Global Healthcare Conference
-
Legend Biotech Shares Rise After Swinging to 2Q Profit, Higher Revenue
-
Legend Biotech Reports Second Quarter 2026 Results and Recent Highlights
Trading Information
- Previous Close Price
- $18.90
- Day Range
- $18.44–19.29
- 52-Week Range
- $16.24–37.50
- Bid/Ask
- $18.80 / $19.33
- Shares Outstanding
- 194.49M
- Market Cap
- $3.75B
- Volume/Avg
- 979,577 / 2M
Key Statistics
- Price/Earnings (Normalized)
- 96.30
- Price/Sales
- 2.81
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- 3,200
- Website
- https://www.legendbiotech.com
Valuation
|
Metric
|
LEGN
|
|---|---|
Price/Earnings (Normalized) | 96.30 |
Price/Book Value | 3.23 |
Price/Sales | 2.81 |
Price/Cash Flow | 51.58 |
Price/Earnings
LEGN
Financial Strength
|
Metric
|
LEGN
|
|---|---|
Quick Ratio | 2.88 |
Current Ratio | 3.04 |
Interest Coverage | −2.87 |
Quick Ratio
LEGN
Profitability
|
Metric
|
LEGN
|
|---|---|
Return on Assets (Normalized) | 2.15% |
Return on Equity (Normalized) | 3.76% |
Return on Invested Capital (Normalized) | 1.99% |
Return on Assets
LEGN
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|?z$@@& | LOCK|#FxL< | $133B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|f!#^vm | LOCK|@hSKm | $83B | |||
| Moderna Inc
MRNA
| LOCK|^NJ%$t> | LOCK|Pxs | $80B | |||
| argenx SE ADR
ARGX
| LOCK|c%@h%b | LOCK|SL | $55B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|#$TjkP< | LOCK|d% | $45B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|^pqg@@Y | LOCK|GL<# | $30B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|>?>c&KH | LOCK|^QR% | $28B | |||
| Incyte Corp
INCY
| LOCK|Cn#<%nF | LOCK|Gg? | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|JNTtH! | LOCK|&CX | $22B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|xTRGK$Y | LOCK|l# | $14B |
United States